Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 3,724 Cr.
- Current Price ₹ 84.2
- High / Low ₹ 85.1 / 26.3
- Stock P/E 84.0
- Book Value ₹ 2.69
- Dividend Yield 0.01 %
- ROCE 37.0 %
- ROE 28.9 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 31.3 times its book value
- Debtor days have increased from 123 to 148 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
(S): Standalone figures, shown where consolidated figures are not available.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 113 | |
| Sales growth | -41% | +85% | +7% | +4% | +6% | +109% | -6% | +83% | +187% | +27% | +74% | +222% | |
| 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 48 | |
| Operating Profit | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 66 |
| OPM % | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 51% | 58% |
| 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 63 |
| Tax % | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | 23% | |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 44 | |
| EPS in Rs | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.15 | 0.42 | 0.22 | 0.50 | 1.00 |
| Dividend Payout % | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 5% | 2% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 222% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 270% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 213% |
| 3 Years: | 234% |
| 1 Year: | 102% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 | 44 |
| Reserves | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 | 74 |
| 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 | 22 | |
| 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 | 34 | |
| Total Liabilities | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 175 |
| 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 | 21 | |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 | 26 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 | 128 | |
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 175 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 | |
| 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 | |
| 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 | |
| Net Cash Flow | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -1 | 2 | -1 | -4 | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 812% | 237% | 7% | 63% | 25% | 81% | 38% | 292% | 64% | -24% | 92% | 17% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 403 | 352 |
| ROCE % | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 37% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue share - Commission Income (Other Operating Revenues) % of revenue from operations ・Standalone data |
|
||||||||||
| Revenue share - Sale of Products (Manufacturing) % of revenue from operations ・Standalone data |
|||||||||||
| Revenue share - Sale of Services (Jobwork/Contract Manufacturing) % of revenue from operations ・Standalone data |
|||||||||||
| Permanent employees on rolls count ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change of Company Name
- NSE approved name change to Shukra Medtech Limited and symbol SHUKRAMED, effective November 20, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.
-
Reg 32
- No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.
-
Unaudited Financial Results For The Quarter Ended 30Th September 2026
- Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2]
It makes and sells pharmaceutical formulations and is now repositioning itself as a pharma-plus-MedTech healthcare group. It describes its business as spanning formulations, medical consumables, MedTech, and analytical testing